Prognosis by initial treatment and baseline risk factors in high-volume metastatic hormone-sensitive prostate cancer: A single-center retrospective study
Year: 2026
Type: preprint
Study design: Observational Study
Abstract: Background Treatment intensification is standard for metastatic hormone-sensitive prostate cancer (mHSPC). However, real-world data comparing initial regimens for high-volume disease remain limited, and the prognostic value of baseline factors is unclear. We compared outcomes according to initial treatment and assessed baseline risk factors. Methods We retrospectively studied patients with high-volume mHSPC treated at a single center between February 2006 and April 2026. Patients received combined androgen blockade (CAB), upfront docetaxel (DTX), or darolutamide plus DTX (DAR + DTX). Endpoints were overall survival (OS), progression-free survival (PFS), and prostate-specific antigen response. Data were analyzed using Kaplan-Meier method, log-rank tests, and Cox regression analysis in EZR. Results We analyzed 114 patients (CAB, 75; upfront DTX, 23; DAR + DTX, 16). The median follow-up was 36.9 months overall and 41.4, 63.1, and 15.4 for the CAB, upfront DTX, and DAR + DTX groups, respectively. OS (p = 0.012) and PFS (p < 0.001) differed significantly between groups. The DAR + DTX group did not reach the median for either OS or PFS and had zero events. On multivariable analysis, an extent of disease score ≥ 3, hemoglobin ≤ 12 g/dL, Gleason Grade Group 5, and performance status ≥ 2 were independently associated with worse OS, while lactate dehydrogenase ≥ 221 U/L was independently associated with worse PFS. The median OS was 95.4, 38.7, and 18.0 months with 0–1, 2, and 3–4 risk factors, respectively (p < 0.001; hazard ratios for death were 2.72 and 9.94). Conclusions Baseline clinical factors were independently associated with prognosis in high-volume mHSPC. A simple risk factor count provided a hypothesis-generating prognostic gradient in this single-center cohort and requires external validation before clinical use. No comparative efficacy conclusion can be drawn for DAR + DTX given its zero events and short follow-up.
Source: Research Square
Institution: Jichi Medical University
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Keywords: metastatic hormone-sensitive prostate cancer, high-volume disease, combined androgen blockade, docetaxel, darolutamide, upfront chemotherapy, prognostic factors, baseline risk factors, overall survival, progression-free survival, PSA response, lactate dehydrogenase, Gleason grade, performance status
Open Access status: green
OpenAlex ID: W7236599681
